Becton, Dickinson and Company (NYSE:BDX) Given Average Rating of “Hold” by Analysts

Shares of Becton, Dickinson and Company (NYSE:BDX) have earned an average recommendation of “Hold” from the sixteen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $184.8571.

BDX has been the subject of a number of recent analyst reports. TD Cowen decreased their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Argus decreased their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Friday, April 10th. They set a “neutral” rating and a $167.00 price target for the company. Barclays upped their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th.

Becton, Dickinson and Company Trading Down 0.3%

Shares of NYSE:BDX opened at $147.38 on Friday. The stock has a market capitalization of $40.61 billion, a PE ratio of 37.31, a P/E/G ratio of 10.46 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The firm has a fifty day moving average price of $152.11 and a 200 day moving average price of $177.44. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period in the prior year, the company earned $3.35 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Crux Wealth Advisors raised its position in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after buying an additional 49 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after buying an additional 53 shares during the last quarter. Camelot Portfolios LLC raised its position in shares of Becton, Dickinson and Company by 1.5% during the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after buying an additional 54 shares during the last quarter. McElhenny Sheffield Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 3.6% during the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after buying an additional 55 shares during the last quarter. Finally, Atlantic Union Bankshares Corp raised its position in shares of Becton, Dickinson and Company by 0.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after buying an additional 57 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.